Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl

被引:0
|
作者
G Monaco
E Decrock
H Akl
R Ponsaerts
T Vervliet
T Luyten
M De Maeyer
L Missiaen
C W Distelhorst
H De Smedt
J B Parys
L Leybaert
G Bultynck
机构
[1] Laboratory of Molecular and Cellular Signaling,Department of Molecular Cell Biology
[2] Campus Gasthuisberg O/N-1 bus 802,Department of Basic Medical Sciences
[3] Herestraat 49,Department of Chemistry
[4] BE-3000 Leuven,Departments of Medicine and Pharmacology
[5] Belgium,undefined
[6] Physiology Group,undefined
[7] Faculty of Medicine and Health Sciences,undefined
[8] Ghent University,undefined
[9] Biomolecular Modelling,undefined
[10] Biochemistry,undefined
[11] Molecular and Structural Biology Section,undefined
[12] Celestijnenlaan 200G bus 2403,undefined
[13] BE-3001 Heverlee,undefined
[14] Belgium,undefined
[15] Comprehensive Cancer Center,undefined
[16] Case Western Reserve University,undefined
来源
关键词
apoptosis; antiapoptotic Bcl-2-family members; calcium signaling; endoplasmic reticulum; intracellular Ca; -release channels;
D O I
暂无
中图分类号
学科分类号
摘要
Antiapoptotic B-cell lymphoma 2 (Bcl-2) targets the inositol 1,4,5-trisphosphate receptor (IP3R) via its BH4 domain, thereby suppressing IP3R Ca2+-flux properties and protecting against Ca2+-dependent apoptosis. Here, we directly compared IP3R inhibition by BH4-Bcl-2 and BH4-Bcl-Xl. In contrast to BH4-Bcl-2, BH4-Bcl-Xl neither bound the modulatory domain of IP3R nor inhibited IP3-induced Ca2+ release (IICR) in permeabilized and intact cells. We identified a critical residue in BH4-Bcl-2 (Lys17) not conserved in BH4-Bcl-Xl (Asp11). Changing Lys17 into Asp in BH4-Bcl-2 completely abolished its IP3R-binding and -inhibitory properties, whereas changing Asp11 into Lys in BH4-Bcl-Xl induced IP3R binding and inhibition. This difference in IP3R regulation between BH4-Bcl-2 and BH4-Bcl-Xl controls their antiapoptotic action. Although both BH4-Bcl-2 and BH4-Bcl-Xl had antiapoptotic activity, BH4-Bcl-2 was more potent than BH4-Bcl-Xl. The effect of BH4-Bcl-2, but not of BH4-Bcl-Xl, depended on its binding to IP3Rs. In agreement with the IP3R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was modulated by the Lys/Asp substitutions. Changing Lys17 into Asp in full-length Bcl-2 significantly decreased its binding to the IP3R, its ability to inhibit IICR and its protection against apoptotic stimuli. A single amino-acid difference between BH4-Bcl-2 and BH4-Bcl-Xl therefore underlies differential regulation of IP3Rs and Ca2+-driven apoptosis by these functional domains. Mutating this residue affects the function of Bcl-2 in Ca2+ signaling and apoptosis.
引用
收藏
页码:295 / 309
页数:14
相关论文
共 50 条
  • [21] The BH4 Domain of Anti-apoptotic Bcl-XL, but Not That of the Related Bcl-2, Limits the Voltage-dependent Anion Channel 1 (VDAC1)-mediated Transfer of Pro-apoptotic Ca2+ Signals to Mitochondria
    Monaco, Giovanni
    Decrock, Elke
    Arbel, Nir
    van Vliet, Alexander R.
    La Rovere, Rita M.
    De Smedt, Humbert
    Parys, Jan B.
    Agostinis, Patrizia
    Leybaert, Luc
    Shoshan-Barmatz, Varda
    Bultynck, Geert
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (14) : 9150 - 9161
  • [22] BH4 domain of Bcl-2 as a novel target for cancer therapy
    Liu, Zhiqing
    Wild, Christopher
    Ding, Ye
    Ye, Na
    Chen, Haiying
    Wold, Eric A.
    Zhou, Jia
    DRUG DISCOVERY TODAY, 2016, 21 (06) : 989 - 996
  • [23] The BH4 domain is required for proangiogenic function of bcl-2 protein
    Gabellini, C.
    Trisciuoglio, D.
    Desideri, M.
    Zupi, G.
    Del Bufalo, D.
    EJC SUPPLEMENTS, 2010, 8 (05): : 104 - 104
  • [24] Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-XL
    Helena LA Vieira
    Patricia Boya
    Isabelle Cohen
    Chahrazed El Hamel
    Delphine Haouzi
    Sabine Druillenec
    Anne-Sophie Belzacq
    Catherine Brenner
    Bernard Roques
    Guido Kroemer
    Oncogene, 2002, 21 : 1963 - 1977
  • [25] Bcl-2 and Bcl-XL inhibit Fas-mediated apoptosis of salivary epithelial cells.
    Kong, LP
    Vela-Roch, N
    Talal, N
    Dang, H
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S354 - S354
  • [26] Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins
    Lutz, RJ
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2000, 28 : 51 - 56
  • [27] BNIP3 heterodimerizes with Bcl-2/Bcl-XL and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites
    Ray, R
    Chen, G
    Vande Velde, C
    Cizeau, J
    Park, JH
    Reed, JC
    Gietz, RD
    Greenberg, AH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (02) : 1439 - 1448
  • [28] Bcl-xL Regulation of InsP3 Receptor Gating Mediated by Dual Ca2+Release Channel BH3 Domains
    Foskett, J. Kevin
    Yang, Jun
    Cheung, King-Ho
    Vais, Horia
    BIOPHYSICAL JOURNAL, 2009, 96 (03) : 391A - 391A
  • [29] NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis
    Hirotani, M
    Zhang, YK
    Fujita, N
    Naito, M
    Tsuruo, T
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (29) : 20415 - 20420
  • [30] BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
    Vervloessem, Tamara
    Sasi, Binu K.
    Xerxa, Elena
    Karamanou, Spyridoula
    Kale, Justin
    La Rovere, Rita M.
    Chakraborty, Supriya
    Sneyers, Flore
    Vogler, Meike
    Economou, Anastassios
    Laurenti, Luca
    Andrews, David W.
    Efremov, Dimitar G.
    Bultynck, Geert
    CELL DEATH & DISEASE, 2020, 11 (09)